Ablynx NV

Ablynx NV specializes in the development of innovative therapeutic compounds based on its proprietary NANOBODY® Technology Platform, targeting diseases such as cancer and immunological disorders. Ablynx NV, founded in 2001, is located in Ghent, Belgium. The company focuses on developing therapies using its NANOBODY technology. Ablynx has successfully raised USD 200.

00 mn through a series of funding rounds, with the latest being a Private Placement/Follow on amounting to USD 200. 00 mn. It has engaged in 18 deals to date. Ablynx's NANOBODY® Technology Platform centers on creating therapeutic compounds from specialized proteins known as antibodies.

These engineered NANOBODY molecules, derived from unique heavy-chain-only antibodies found in species like camels and llamas, are capable of binding multiple targets, enhancing efficacy in oncology and immunology. The company caters to healthcare providers and patients, providing advanced treatments for cancer and immune response modulation across North America, Europe, and select regions in Asia. In 2024, Ablynx reported a revenue of USD 133. 02 mn and an EBITDA of USD 113.

25 mn, generating income through strategic partnerships and B2B transactions in the biopharmaceutical sector. Ablynx NV is focused on expanding its product pipeline and enhancing its market presence. Upcoming launches of new NANOBODY therapies are anticipated, with timelines yet to be announced. The company seeks to penetrate additional geographic markets, targeting regions in Asia and Europe.

The recent funding will be utilized to support these initiatives, alongside plans for further partnerships, following the previous exits of Gimv and Sofinnova Partners in 2013.